1-Minute Summary: Biomarkers in asthma management: Time to move forward

Expert Name
Prof. Kjell Alving

Alving K, Diamant Z, Lucas S, et al. Point‐of‐care biomarkers in asthma management: Time to move forward Allergy. Allergy. 2020;75(4):995‐997. The Global Initiative for Asthma (GINA) report has directed clinical guidelines for asthma since 2014. Evidence comes from randomised controlled trials, but not from real-world or observational studies, which could be a limitation [1]. Asthma is a heterogeneous condition with…

Holistic View on Asthma

Expert Name
Prof. Zuzana Diamant

In the past 15 years, striking progress has been made in our understanding of the mechanisms underlying chronic inflammatory airway disease as well as the predisposing and interfering factors. These insights have resulted in a more holistic and personalised approach to the diagnosis and management of chronic inflammatory airway diseases including their comorbidities. At the annual congress of the European…

Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics

Expert Name
Prof. Zuzana Diamant

Introduction Over the past two centuries, there has been a gradual paradigm change in the way we look at chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), shifting away from prototypic, organ-centred disease labels, coined by William Osler at the end of the 19th century, to differentiated disease subsets [1]. During the second half of the…

Dupilumab improves outcomes in chronic rhinosinusitis with nasal polyps and asthma

Expert Name
Dr Jorge Maspero

In a pooled analysis of the SINUS-24 and SINUS-52 trials, dupilumab significantly improved both upper and lower airway outcomes compared with placebo in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma [1]. Dr Jorge Maspero (Fundación CIDEA, Argentina) presented the research in a late-breaking clinical trial session, pointing out that asthma and chronic rhinosinusitis with nasal polyps…

Benralizumab does not ameliorate COPD exacerbations

Expert Name
Prof. Gerard Criner

New research shows that the asthma drug benralizumab did not statistically decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, a history of frequent moderate and/or severe exacerbations, and eosinophilic inflammation; although the team did report numeric decreases (GALATHEA/TERRANOVA trials). The data were published in the New England Journal of Medicine in conjunction with Prof. Gerard…